Last update: Feb. 15, 2016

Spiramycin

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

It is assumed that excretion into breast milk achieves bacteriostatic concentrations.
A latest update no published data were found on excretion into breast milk.

Because a high molecular weight it seems unlikely an excretion into breast milk in significant amount.
A low oral bioavailability further reduced with simultaneous food intake impairs the appearance in the infant plasma from ingested milk except in preterm babies and those in the immediate neonatal period, which may have increased intestinal permeability.

Macrolide-based medication that is used in infants.
Until more published data on this drug regarding breastfeeding is available, safer alternatives with better known drugs should be preferable especially during the neonatal period and in case of prematurity..

Take into account the possible negative cultures in febrile infants whose mothers take antibiotics

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Spiramycin is also known as


Spiramycin in other languages or writings:

Group

Spiramycin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Spiramycin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 30 - 40 %
Molecular weight 843 daltons
Protein Binding 10 - 25 %
VD 3,8 - 7,4 l/Kg
Tmax 0,5 - 4 hours
T1/2 2 - 8 hours

References

  1. Rubinstein E, Keller N. Spiramycin renaissance. J Antimicrob Chemother. 1998 Abstract Full text (link to original source) Full text (in our servers)
  2. Hacker M, Richter R, Gümbel H, Richter T, Ohrloff C. [Toxoplasmosis retinochorioiditis, a therapy comparison between spiramycin and pyrimethamine/sulfadiazine]. Klin Monbl Augenheilkd. 1998 Abstract
  3. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989 Abstract
  4. Ziv G, Bogin E, Shani J, Sulman FG. Distribution and blood-to-milk transfer of labeled antibiotics. Antimicrob Agents Chemother. 1973 Abstract

Total visits

14,016

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM